SCHEMBL31729265

SCHEMBL31729265

COc1cc(F)c(-c2cccc(Cl)c2)c2ncnc(N)c12

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MAP4K4 O95819 3/20 0.43
▸ LIMK1 P53667 1/20 0.41
▸ FYN P06241 1/20 0.41
▸ CLK1 P49759 2/20 0.41
▸ ADK P55263 2/20 0.40
▸ ABL1 P00519 2/20 0.40
▸ EGFR P00533 2/20 0.40
▸ SRC P12931 2/20 0.40
▸ KDR P35968 2/20 0.40
▸ DHPS P49366 2/20 0.40
▸ ABL2 P42684 1/20 0.40
▸ PIK3CD O00329 1/20 0.40
▸ HCK P08631 1/20 0.40
▸ PIK3CA P42336 1/20 0.40
▸ PIK3CB P42338 1/20 0.40
▸ MTOR P42345 1/20 0.40
▸ PIK3CG P48736 1/20 0.40
▸ EPHB4 P54760 1/20 0.40
▸ PRKDC P78527 1/20 0.40
▸ PI4KB Q9UBF8 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31729150 0.84 ADK (0.43) MAP4K4LIMK1FYNCLK1ADK
SCHEMBL31728147 0.82 MAP4K4 (0.47) MAP4K4LIMK1CLK1ADKABL1
SCHEMBL31727817 0.80 FYN (0.48) MAP4K4LIMK1FYNCLK1ABL1
SCHEMBL31727952 0.80 EIF2AK3 (0.42) MAP4K4LIMK1ABL1EGFRSRC
SCHEMBL31729157 0.79 PDE5A (0.39) FYNCLK1ABL1EGFRSRC
SCHEMBL31728910 0.79 FYN (0.45) MAP4K4LIMK1FYNCLK1ADK
SCHEMBL31729192 0.77 PIK3CD (0.34) MAP4K4LIMK1CLK1ADKABL1
SCHEMBL31728078 0.77 CLK1 (0.48) MAP4K4LIMK1FYNCLK1ADK
SCHEMBL31728478 0.75 MAP4K4 (0.51) MAP4K4LIMK1CLK1ADKABL1
SCHEMBL31729145 0.72 PDE5A (0.44) MAP4K4LIMK1CLK1ABL1EGFR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2025235874-A1 HETEROCYCLICS AS EGFR INHIBITORS SCHRÖDINGER, INC. (US) 2025-11-13 — — WO disclosed
Send feedback